Vertex Pharmaceuticals (VRTX) Net Cash Flow (2009 - 2026)

Vertex Pharmaceuticals' Net Cash Flow history runs 18 years deep, the most recent figure standing at $457.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 453.08% year-over-year to $457.4 million; the TTM figure through Mar 2026 stood at $799.4 million (up 117.81% YoY), while the FY2025 annual figure was $424.7 million, up 107.38% from the prior year.
• Net Cash Flow was $457.4 million for Q1 2026 at Vertex Pharmaceuticals, up from $132.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.3 billion in Q4 2022 to a low of -$4.6 billion in Q2 2024.
• Historically, Net Cash Flow has averaged -$76.5 million across 5 years, with a median of $239.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow surged 558.1% in 2022, then slumped 639.74% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $1.3 billion in 2022, then tumbled by 159.63% to -$771.7 million in 2023, then climbed by 18.54% to -$628.6 million in 2024, then soared by 121.11% to $132.7 million in 2025, then jumped by 244.69% to $457.4 million in 2026.
• The last three Net Cash Flow figures came in at $457.4 million (Q1 2026), $132.7 million (Q4 2025), and -$30.1 million (Q3 2025), per Business Quant data.